Introduction
Breast cancer (BC) is among the most common cancers worldwide, particularly in females, and a significant portion of these cases are linked to inherited genetic mutations. These mutations happen specifically in BRCA1 and BRCA2 genes, increasing an individual's lifetime risk of developing BC and hugely influencing how the tumor develops. Therefore, understanding a BC patient's genetic background becomes a concrete step toward enhancing modern medicine for BC, as it may directly affect diagnosis, treatment, and prevention.
This study explores the role of cancer genetic counseling (CGC) in the management of hereditary BC. It presents how identifying gene variants could play a key role in strategizing personalized treatments and enabling preventive care for at-risk family members. The topic is extremely important for its shift toward precision oncology, tailoring care towards the patient's unique genetic profile.
Key Concepts
Hereditary BC refers to cases resulting from inherited mutations in specific genes passed down through families. Pathogenic (P)/likely pathogenic (LP) variants account for about 5-10% of female BC cases and 16% of male BC cases. The most well-known mutations are in BRCA1 and BRCA2 genes, which are crucial in the process of DNA repair. When these genes are altered, cells are more likely to accumulate mutations that potentially lead to cancer.
Cancer genetic counseling (CGC) is a process that advises patients about their genetic risk, helps interpret test results, and aids in making informed decisions about health care. Multigene panel testing is a method that allows multiple cancer-related genes to be analyzed at once, increasing efficiency and likelihood of identifying relevant mutations.
In this study, the focus is on human patients with BC, including both early-stage and metastatic cases. It also takes into consideration the health of members in affected families through cascade testing, where relatives are tested for genetic mutations.
The key biological mechanism involved in this research is the role of gene mutations in disrupting normal cell cycle regulation and DNA repair.
Methods
The study reviews current advances and practices in genetic testing for hereditary BC. Rather than conducting a single experiment, the authors analyzed data from multiple clinical studies involving human BC patients.
It examines the use of CGC, which involves pre-test risk assessment, patient education, genetic testing, and post-test interpretation. In addition, cascade testing of family members was evaluated to assess its role in prevention. Outcomes were measured by how genetic testing influenced clinical management, including surgery, targeted therapies, prevention, and follow-up care.
Results and Limitations
The identification of BRCA1/2 mutations significantly improves BC management, helping guide treatment decisions and increasing survival rates. Additionally, personalized follow-up is important due to increased risks of other cancers. However, not all genetic variants provide clear guidance for treatment. Risk prediction remains uncertain due to environmental and genetic differences. Access to CGC may be uneven, and some may be less effective than others in various populations. These challenges may limit the impact of personalized care. The study also suggests that there could potentially be negative psychological, social effects from participating in CGC.
Conclusion
Highlighting the importance of CGC and genetic testing in the management of hereditary BC, the study provides insights about potential directions of improvements in cancer treatment. As researchers move into the era of precision oncology, identification of genetic variants paves the way for more personalized approaches to prevention, treatment, and long-term health care.
